Streetbeat News

Revenues

MMSI

Merit Medical Systems (NASDAQ:MMSI) has received varied analyst ratings over the past three months, with 3 bullish and 1 somewhat bullish out of 4 total ratings. The average 12-month price target is $93.25, with a high of $100.00 and a low of $81.00, reflecting a 4.78% increase from the previous target of $89.00. Analysts from Canaccord Genuity, Barrington Research, and Needham have updated their ratings and price targets, indicating a positive outlook on the company's performance. Merit Medical Systems specializes in medical equipment for interventional procedures and has shown strong financial indicators such as revenue growth, net margin, ROE, ROA, and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 2:00 pm

NVRO

Nevro (NYSE:NVRO) has received mixed analyst ratings over the last three months, with 1 somewhat bullish, 4 indifferent, and 1 somewhat bearish. The average 12-month price target is now $19.00, down from $22.12. Analysts from Canaccord Genuity, RBC Capital, Truist Securities, JP Morgan, Piper Sandler, and Morgan Stanley have adjusted their ratings and price targets. Nevro's financials show a revenue growth of 3.38%, a net margin of -22.61%, an ROE of -8.09%, an ROA of -4.15%, and a debt-to-equity ratio of 0.68.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 2:00 pm

GSK

MRK

The FDA has issued a second Complete Response Letter (CRL) to Merck & Co Inc (NYSE:MRK) for gefapixant, a drug candidate for treating refractory chronic cough (RCC) and unexplained chronic cough (UCC) in adults, citing insufficient evidence of effectiveness. The CRL did not question the safety of gefapixant. Merck is currently reviewing the FDA's feedback. This development may benefit GSK Plc (NYSE:GSK), which has a competing chronic cough drug, camlipixant, in Phase 3 trials with expected approval in 2026. MRK's stock price saw a slight increase in premarket trading.

Portfolio Pulse from Vandana Singh

December 21, 2023 | 1:51 pm

NHWK

NightHawk Biosciences (NYSE:NHWK) has successfully completed a demonstration run for a microbial vaccine program at its Scorpius BioManufacturing subsidiary, which is part of a multi-million-dollar project funded by NIH and DTRA for a top-tier research university. The next phase will involve scaling up cGMP manufacturing for a phase 1 trial targeting infectious disease. The company's CDMO services are in high demand due to a scarcity of large molecule manufacturing capacity.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 1:47 pm

TGL

Treasure Global has launched 10 mini-games in ZCITY 3D World, powered by its Artificial Intelligence Game Creator. This move aims to tap into the growing global gaming market, projected to generate $212.4 billion in revenue by 2026. The mobile gaming market, where ZCITY's mini-games are positioned, is expected to contribute $92.6 billion. The online gaming market saw a 9.8% growth in 2023. The AI-powered mini-games are expected to enhance user experience and provide new revenue streams through in-game purchases and AI-driven marketing. Treasure Global's CEO, Sam Teo, believes this integration aligns with the market's growth and positions ZCITY as a leader in AI-enhanced entertainment.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 1:42 pm

CTAS

Cintas Corporation has increased its annual revenue forecast from the range of $9.40 billion to $9.52 billion to a new range of $9.48 billion to $9.56 billion. Additionally, the company has raised its earnings per share (EPS) guidance from $14.00-$14.45 to $14.35-$14.65.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 1:33 pm

MULN

Mullen Automotive, Inc. has delivered 38 Class 3 electric vehicles to Randy Marion Automotive Group, invoicing them for $2.5 million. This delivery is part of a larger order of 1,000 vehicles valued at $63 million, with the majority to be delivered in 2024. Mullen's Tunica, Mississippi facility plans to produce 150 vehicles in 2023 and has an annual capacity of 3,000 vehicles per shift. The Mullen THREE offers significant cargo capacity and maneuverability, with strong demand for the all-electric lineup. Mullen began deliveries to Randy Marion in September 2023, and Randy Marion received a license to retail Mullen's commercial EVs in November 2023.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 1:14 pm

SLNH

Soluna Holdings, Inc. (NASDAQ:SLNH) announced significant business achievements and project developments, including revenue boosts for Project Dorothy and Sophie due to a spike in hashprice. The company joined ERCOT's Demand Response program and is progressing with Project Dorothy 2 and Project Kati. Notable increases in hashprice in November and December have improved financial performance for Project Dorothy 1B and Project Sophie. Updated reporting methodology for power and hashrate data was also introduced.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 1:06 pm

AIR

TGI

AAR CORP. (NYSE:AIR) has agreed to acquire Triumph Group's (NYSE:TGI) Product Support business for $725 million in cash. The acquisition is expected to scale AAR's repair capabilities, be accretive to margins, expand the customer base and global footprint, and generate cost synergies of $10 million. Triumph Product Support is anticipated to bring in $280 million in revenue and $55 million in EBITDA by March 31, 2024. The deal, expected to close in Q1 2024, is supported by a bridge facility and may include a mix of debt and equity for financing. AAR aims for a pro forma net leverage of approximately 3.0x at closing.

Portfolio Pulse from Benzinga Newsdesk

December 21, 2023 | 1:02 pm

SPG

Simon Property Group (NYSE:SPG) has received mixed ratings from 4 analysts in the past three months, with an average 12-month price target of $143.25, up from the previous $136.00. Analysts from Morgan Stanley, Piper Sandler, Truist Securities, and Stifel have adjusted their ratings and price targets, reflecting their views on the company's market conditions and performance. Simon Property Group is a major REIT with a diverse portfolio and has shown strong financial health indicators such as revenue growth, net margin, ROE, and ROA, but carries a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

December 21, 2023 | 1:01 pm